{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:37:34Z","timestamp":1792183054685,"version":"4.4.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-61695-0","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T15:40:03Z","timestamp":1752507603000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Structure-guided engineering of snake toxins for selective modulation of adrenergic and muscarinic receptors"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7474-0536","authenticated-orcid":false,"given":"Yixuan","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binbin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haizhan","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maikun","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9257-1438","authenticated-orcid":false,"given":"Yuyong","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"61695_CR1","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1002\/pro.5560020802","volume":"2","author":"AD Strosberg","year":"1993","unstructured":"Strosberg, A. D. Structure, function, and regulation of adrenergic receptors. Protein Sci. 2, 1198\u20131209 (1993).","journal-title":"Protein Sci."},{"key":"61695_CR2","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nrd2379","volume":"6","author":"J Wess","year":"2007","unstructured":"Wess, J., Eglen, R. M. & Gautam, D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat. Rev. Drug Discov. 6, 721\u2013733 (2007).","journal-title":"Nat. Rev. Drug Discov."},{"key":"61695_CR3","doi-asserted-by":"crossref","unstructured":"Wess, J. Novel muscarinic receptor mutant mouse models. Handb. Exp. Pharmacol. 2012, 95\u2212117 (2012).","DOI":"10.1007\/978-3-642-23274-9_6"},{"key":"61695_CR4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1146\/annurev.pa.33.040193.001331","volume":"33","author":"RR Ruffolo Jr.","year":"1993","unstructured":"Ruffolo, R. R. Jr., Nichols, A. J., Stadel, J. M. & Hieble, J. P. Pharmacologic and therapeutic applications of alpha 2-adrenoceptor subtypes. Annu Rev. Pharm. Toxicol. 33, 243\u2013279 (1993).","journal-title":"Annu Rev. Pharm. Toxicol."},{"key":"61695_CR5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S0165-6147(97)90625-8","volume":"18","author":"E MacDonald","year":"1997","unstructured":"MacDonald, E., Kobilka, B. K. & Scheinin, M. Gene targeting\u2013homing in on alpha 2-adrenoceptor-subtype function. Trends Pharm. Sci. 18, 211\u2013219 (1997).","journal-title":"Trends Pharm. Sci."},{"key":"61695_CR6","doi-asserted-by":"crossref","unstructured":"Furchgott, R. F. in Catecholamines (eds H. Blaschko & E. Muscholl) 283\u2212335 (Springer Berlin Heidelberg, 1972).","DOI":"10.1007\/978-3-642-65249-3_9"},{"key":"61695_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0014-2999(98)00682-7","volume":"361","author":"JR Docherty","year":"1998","unstructured":"Docherty, J. R. Subtypes of functional alpha1- and alpha2-adrenoceptors. Eur. J. Pharm. 361, 1\u201315 (1998).","journal-title":"Eur. J. Pharm."},{"key":"61695_CR8","doi-asserted-by":"publisher","first-page":"R287","DOI":"10.1152\/ajpregu.00123.2002","volume":"283","author":"M Philipp","year":"2002","unstructured":"Philipp, M., Brede, M. & Hein, L. Physiological significance of alpha(2)-adrenergic receptor subtype diversity: one receptor is not enough. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283, R287\u2013R295 (2002).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"61695_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3389\/fpsyt.2017.00042","volume":"8","author":"V Maletic","year":"2017","unstructured":"Maletic, V., Eramo, A., Gwin, K., Offord, S. J. & Duffy, R. A. The role of norepinephrine and its alpha-adrenergic receptors in the pathophysiology and treatment of major depressive disorder and schizophrenia: a systematic review. Front Psychiatry 8, 42 (2017).","journal-title":"Front Psychiatry"},{"key":"61695_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/jpet.120.265942","volume":"375","author":"H Neyama","year":"2020","unstructured":"Neyama, H., Dozono, N., Uchida, H. & Ueda, H. Mirtazapine, an alpha2 antagonist-type antidepressant, reverses pain and lack of morphine analgesia in fibromyalgia-like mouse models. J. Pharm. Exp. Ther. 375, 1\u20139 (2020).","journal-title":"J. Pharm. Exp. Ther."},{"key":"61695_CR11","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00109-009-0555-z","volume":"88","author":"F Zhang","year":"2010","unstructured":"Zhang, F., Wu, R., Qiang, X., Zhou, M. & Wang, P. Antagonism of alpha2A-adrenoceptor: a novel approach to inhibit inflammatory responses in sepsis. J. Mol. Med. (Berl.) 88, 289\u2013296 (2010).","journal-title":"J. Mol. Med. (Berl.)"},{"key":"61695_CR12","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1126\/science.273.5276.803","volume":"273","author":"RE Link","year":"1996","unstructured":"Link, R. E. et al. Cardiovascular regulation in mice lacking alpha2-adrenergic receptor subtypes b and c. Science 273, 803\u2013805 (1996).","journal-title":"Science"},{"key":"61695_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1003","volume":"10","author":"RGW Proudman","year":"2022","unstructured":"Proudman, R. G. W., Akinaga, J. & Baker, J. G. The signaling and selectivity of alpha-adrenoceptor agonists for the human alpha2A, alpha2B and alpha2C-adrenoceptors and comparison with human alpha1 and beta-adrenoceptors. Pharm. Res Perspect. 10, e01003 (2022).","journal-title":"Pharm. Res Perspect."},{"key":"61695_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.936","volume":"10","author":"RGW Proudman","year":"2022","unstructured":"Proudman, R. G. W., Akinaga, J. & Baker, J. G. The affinity and selectivity of alpha-adrenoceptor antagonists, antidepressants and antipsychotics for the human alpha2A, alpha2B, and alpha2C-adrenoceptors and comparison with human alpha1 and beta-adrenoceptors. Pharm. Res. Perspect. 10, e00936 (2022).","journal-title":"Pharm. Res. Perspect."},{"key":"61695_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2174\/156802607779318235","volume":"7","author":"F Gentili","year":"2007","unstructured":"Gentili, F., Pigini, M., Piergentili, A. & Giannella, M. Agonists and antagonists targeting the different alpha2-adrenoceptor subtypes. Curr. Top. Med. Chem. 7, 163\u2013186 (2007).","journal-title":"Curr. Top. Med. Chem."},{"key":"61695_CR16","doi-asserted-by":"crossref","unstructured":"Wu, Y., Zeng, L. & Zhao, S. Ligands of adrenergic receptors: a structural point of view. Biomolecules 11, 936 (2021).","DOI":"10.3390\/biom11070936"},{"key":"61695_CR17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/0163-7258(93)90027-B","volume":"58","author":"MP Caulfield","year":"1993","unstructured":"Caulfield, M. P. Muscarinic receptors\u2013characterization, coupling and function. Pharm. Ther. 58, 319\u2013379 (1993).","journal-title":"Pharm. Ther."},{"key":"61695_CR18","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0031-6997(24)01362-0","volume":"50","author":"MP Caulfield","year":"1998","unstructured":"Caulfield, M. P. & Birdsall, N. J. International union of pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharm. Rev. 50, 279\u2013290 (1998).","journal-title":"Pharm. Rev."},{"key":"61695_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1006\/phrs.2001.0835","volume":"44","author":"S Dhein","year":"2001","unstructured":"Dhein, S., van Koppen, C. J. & Brodde, O. E. Muscarinic receptors in the mammalian heart. Pharm. Res. 44, 161\u2013182 (2001).","journal-title":"Pharm. Res."},{"key":"61695_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1152\/physiolgenomics.00062.2017","volume":"50","author":"HC Saternos","year":"2018","unstructured":"Saternos, H. C. et al. Distribution and function of the muscarinic receptor subtypes in the cardiovascular system. Physiol. Genom. 50, 1\u20139 (2018).","journal-title":"Physiol. Genom."},{"key":"61695_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0079-6123(03)45003-6","volume":"145","author":"LA Volpicelli","year":"2004","unstructured":"Volpicelli, L. A. & Levey, A. I. Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus. Prog. Brain Res. 145, 59\u201366 (2004).","journal-title":"Prog. Brain Res."},{"key":"61695_CR22","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nrd4295","volume":"13","author":"AC Kruse","year":"2014","unstructured":"Kruse, A. C. et al. Muscarinic acetylcholine receptors: novel opportunities for drug development. Nat. Rev. Drug Discov. 13, 549\u2013560 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"61695_CR23","first-page":"413","volume":"14","author":"DJ Foster","year":"2012","unstructured":"Foster, D. J., Jones, C. K. & Conn, P. J. Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling. Discov. Med. 14, 413\u2013420 (2012).","journal-title":"Discov. Med."},{"key":"61695_CR24","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1021\/cn200110q","volume":"3","author":"D Dencker","year":"2012","unstructured":"Dencker, D. et al. Muscarinic acetylcholine receptor subtypes as potential drug targets for the treatment of schizophrenia, drug abuse and parkinson\u2019s disease. ACS Chem. Neurosci. 3, 80\u201389 (2012).","journal-title":"ACS Chem. Neurosci."},{"key":"61695_CR25","doi-asserted-by":"crossref","unstructured":"Myslivecek, J. Multitargeting nature of muscarinic orthosteric agonists and antagonists. Front. Physiol. 13, 974160 (2022).","DOI":"10.3389\/fphys.2022.974160"},{"key":"61695_CR26","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","volume":"165","author":"A Shekhar","year":"2008","unstructured":"Shekhar, A. et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am. J. Psychiatry 165, 1033\u20131039 (2008).","journal-title":"Am. J. Psychiatry"},{"key":"61695_CR27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejphar.2008.12.044","volume":"605","author":"JN Heinrich","year":"2009","unstructured":"Heinrich, J. N. et al. Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur. J. Pharm. 605, 53\u201356 (2009).","journal-title":"Eur. J. Pharm."},{"key":"61695_CR28","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/med.20166","volume":"30","author":"M De Amici","year":"2010","unstructured":"De Amici, M., Dallanoce, C., Holzgrabe, U., Trankle, C. & Mohr, K. Allosteric ligands for G protein-coupled receptors: a novel strategy with attractive therapeutic opportunities. Med. Res. Rev. 30, 463\u2013549 (2010).","journal-title":"Med. Res. Rev."},{"key":"61695_CR29","doi-asserted-by":"publisher","first-page":"523","DOI":"10.2174\/1389557054023251","volume":"5","author":"NJ Birdsall","year":"2005","unstructured":"Birdsall, N. J. & Lazareno, S. Allosterism at muscarinic receptors: ligands and mechanisms. Mini Rev. Med. Chem. 5, 523\u2013543 (2005).","journal-title":"Mini Rev. Med. Chem."},{"key":"61695_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd2760","volume":"8","author":"PJ Conn","year":"2009","unstructured":"Conn, P. J., Christopoulos, A. & Lindsley, C. W. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat. Rev. Drug Discov. 8, 41\u201354 (2009).","journal-title":"Nat. Rev. Drug Discov."},{"key":"61695_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.tips.2012.10.003","volume":"34","author":"JR Lane","year":"2013","unstructured":"Lane, J. R., Sexton, P. M. & Christopoulos, A. Bridging the gap: bitopic ligands of G-protein-coupled receptors. Trends Pharm. Sci. 34, 59\u201366 (2013).","journal-title":"Trends Pharm. Sci."},{"key":"61695_CR32","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1124\/mi.9.3.6","volume":"9","author":"C Valant","year":"2009","unstructured":"Valant, C., Sexton, P. M. & Christopoulos, A. Orthosteric\/allosteric bitopic ligands: going hybrid at GPCRs. Mol. Inter. 9, 125\u2013135 (2009).","journal-title":"Mol. Inter."},{"key":"61695_CR33","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1124\/mol.106.033746","volume":"72","author":"T Steinfeld","year":"2007","unstructured":"Steinfeld, T., Mammen, M., Smith, J. A., Wilson, R. D. & Jasper, J. R. A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor. Mol. Pharm. 72, 291\u2013302 (2007).","journal-title":"Mol. Pharm."},{"key":"61695_CR34","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41573-020-0062-z","volume":"19","author":"AP Davenport","year":"2020","unstructured":"Davenport, A. P., Scully, C. C. G., de Graaf, C., Brown, A. J. H. & Maguire, J. J. Advances in therapeutic peptides targeting G protein-coupled receptors. Nat. Rev. Drug Discov. 19, 389\u2013413 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"61695_CR35","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0163-7258(99)00064-9","volume":"85","author":"KN Bradley","year":"2000","unstructured":"Bradley, K. N. Muscarinic toxins from the green mamba. Pharm. Ther. 85, 87\u2013109 (2000).","journal-title":"Pharm. Ther."},{"key":"61695_CR36","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1111\/j.1471-4159.2009.06092.x","volume":"109","author":"D Servent","year":"2009","unstructured":"Servent, D. & Fruchart-Gaillard, C. Muscarinic toxins: tools for the study of the pharmacological and functional properties of muscarinic receptors. J. Neurochem. 109, 1193\u20131202 (2009).","journal-title":"J. Neurochem."},{"key":"61695_CR37","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.biochi.2014.04.009","volume":"103","author":"G Blanchet","year":"2014","unstructured":"Blanchet, G. et al. Polypharmacology profiles and phylogenetic analysis of three-finger toxins from mamba venom: case of aminergic toxins. Biochimie 103, 109\u2013117 (2014).","journal-title":"Biochimie"},{"key":"61695_CR38","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1523\/JNEUROSCI.13-10-04293.1993","volume":"13","author":"SI Max","year":"1993","unstructured":"Max, S. I., Liang, J. S. & Potter, L. T. Purification and properties of m1-toxin, a specific antagonist of m1 muscarinic receptors. J. Neurosci. 13, 4293\u20134300 (1993).","journal-title":"J. Neurosci."},{"key":"61695_CR39","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1124\/mol.105.020883","volume":"69","author":"C Fruchart-Gaillard","year":"2006","unstructured":"Fruchart-Gaillard, C., Mourier, G., Marquer, C., Menez, A. & Servent, D. Identification of various allosteric interaction sites on M1 muscarinic receptor using 125I-Met35-oxidized muscarinic toxin 7. Mol. Pharm. 69, 1641\u20131651 (2006).","journal-title":"Mol. Pharm."},{"key":"61695_CR40","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1476-5381.1996.tb15400.x","volume":"118","author":"MC Olianas","year":"1996","unstructured":"Olianas, M. C., Adem, A., Karlsson, E. & Onali, P. Rat striatal muscarinic receptors coupled to the inhibition of adenylyl cyclase activity: potent block by the selective m4 ligand muscarinic toxin 3 (MT3). Br. J. Pharm. 118, 283\u2013288 (1996).","journal-title":"Br. J. Pharm."},{"key":"61695_CR41","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/j.1476-5381.2011.01468.x","volume":"164","author":"K Nareoja","year":"2011","unstructured":"Nareoja, K. et al. Adrenoceptor activity of muscarinic toxins identified from mamba venoms. Br. J. Pharm. 164, 538\u2013550 (2011).","journal-title":"Br. J. Pharm."},{"key":"61695_CR42","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41589-023-01389-0","volume":"20","author":"Q Guo","year":"2024","unstructured":"Guo, Q. et al. A method for structure determination of GPCRs in various states. Nat. Chem. Biol. 20, 74\u201382 (2024).","journal-title":"Nat. Chem. Biol."},{"key":"61695_CR43","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41586-023-06415-8","volume":"620","author":"JL Watson","year":"2023","unstructured":"Watson, J. L. et al. De novo design of protein structure and function with RFdiffusion. Nature 620, 1089\u20131100 (2023).","journal-title":"Nature"},{"key":"61695_CR44","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41586-023-06953-1","volume":"626","author":"S V\u00e1zquez Torres","year":"2024","unstructured":"V\u00e1zquez Torres, S. et al. De novo design of high-affinity binders of bioactive helical peptides. Nature 626, 435\u2013442 (2024).","journal-title":"Nature"},{"key":"61695_CR45","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1021\/acs.jnatprod.5b01055","volume":"79","author":"DJ Newman","year":"2016","unstructured":"Newman, D. J. & Cragg, G. M. Natural products as sources of new drugs from 1981 to 2014. J. Nat. Prod. 79, 629\u2013661 (2016).","journal-title":"J. Nat. Prod."},{"key":"61695_CR46","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.4155\/fmc.14.85","volume":"6","author":"N Gilles","year":"2014","unstructured":"Gilles, N. & Servent, D. The European FP7 venomics project. Future Med. Chem. 6, 1611\u20131612 (2014).","journal-title":"Future Med. Chem."},{"key":"61695_CR47","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1111\/j.1742-1241.2006.01196.x","volume":"60","author":"B Gallwitz","year":"2006","unstructured":"Gallwitz, B. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data. Int J. Clin. Pr. 60, 1654\u20131661 (2006).","journal-title":"Int J. Clin. Pr."},{"key":"61695_CR48","doi-asserted-by":"crossref","unstructured":"Rubiu, E. et al. A benefit\/risk assessment of intrathecal ziconotide in chronic pain: a narrative review. J. Clin. Med. 13, 1644 (2024).","DOI":"10.3390\/jcm13061644"},{"key":"61695_CR49","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1126\/science.aax2517","volume":"369","author":"S Maeda","year":"2020","unstructured":"Maeda, S. et al. Structure and selectivity engineering of the M(1) muscarinic receptor toxin complex. Science 369, 161\u2013167 (2020).","journal-title":"Science"},{"key":"61695_CR50","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290\u2013296 (2017).","journal-title":"Nat. Methods"},{"key":"61695_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18952-1","volume":"11","author":"T Bepler","year":"2020","unstructured":"Bepler, T., Kelley, K., Noble, A. J. & Berger, B. Topaz-Denoise: general deep denoising models for cryoEM and cryoET. Nat. Commun. 11, 5208 (2020).","journal-title":"Nat. Commun."},{"key":"61695_CR52","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen, E. F. et al. UCSF Chimera\u2013a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605\u20131612 (2004).","journal-title":"J. Comput. Chem."},{"key":"61695_CR53","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D. Biol. Crystallogr. 60, 2126\u20132132 (2004).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"61695_CR54","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D. Biol. Crystallogr. 66, 213\u2013221 (2010).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"61695_CR55","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1126\/science.add2187","volume":"378","author":"J Dauparas","year":"2022","unstructured":"Dauparas, J. et al. Robust deep learning-based protein sequence design using ProteinMPNN. Science 378, 49\u201356 (2022).","journal-title":"Science"},{"key":"61695_CR56","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583\u2013589 (2021).","journal-title":"Nature"},{"key":"61695_CR57","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/j.cell.2019.04.044","volume":"177","author":"A Inoue","year":"2019","unstructured":"Inoue, A. et al. Illuminating G-protein-coupling selectivity of GPCRs. Cell 177, 1933\u20131947.e1925 (2019).","journal-title":"Cell"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61695-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61695-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61695-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T10:52:11Z","timestamp":1757242331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-61695-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["61695"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-61695-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"25 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.T., Q.G., Y.Zhong, and H.T. have filed an invention patent for the toxin variants described in this work (application number: CN202510869589.7; status: pending). The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6478"}}